• Disease areas
  • Science & technology
  • Partnering
  • Sustainable business
  • Careers
  • About us
  • Our products
  • Patients
  • Investors
  • News & media
  • Healthcare professionals
  • Contact us

Latest news

{{'2025-09-10T05:00:45Z' | dateFormatFilter}}

Novo Nordisk to streamline operations and reinvest for growth

Read more

{{'2025-09-05T06:01:42Z' | dateFormatFilter}}

Novo Nordisk to present new semaglutide data on ‘food noise’, body composition and cardiovascular benefits, as well as pipeline data at the EASD diabetes congress

Read more

{{'2025-08-31T07:09:33Z' | dateFormatFilter}}

Novo Nordisk’s Wegovy® cuts risk of heart attack, stroke or death by 57% compared to tirzepatide in real-world study of people with obesity and cardiovascular disease

Read more

News archive

Investors

Share price

{{priceData.date}} {{priceData.time}}

{{priceData.currentPrice}} {{priceData.currency}}
Go to stock watch {{priceData.change}} {{priceData.currency}}

Quick links

Visit Capital Markets day Stock information Press releases and company announcements R&D Pipeline Upcoming events

Annual Report

Cover page of the Novo Nordisk Annual Report 2024 - Novo Nordisk employees Steve Piaget and Marie Ange Gahozo from our site in Kalundborg, Denmark, overseeing an active construction project

Annual Report 2024

Download Annual Report

NOVO NORDISK HQ

Novo Nordisk A/S
Novo Alle 1
2880 Bagsværd
Denmark
+45-4444-8888
CVR-no. 24256790

 

Our medicines are for the approved indication for which they are authorised in the local country or region. For more information, please visit our product page

Helpful links

  • Report a side effect
  • Patient help
  • Supplier help
  • Product list
  • Contact us
  • Annual Report
  • ESG reporting
  • Novo Nordisk Foundation

Follow us

  • Social media community guidelines
  • LinkedIn
  • YouTube
  • Facebook
  • X (Twitter)
  • Instagram
  • TikTok

Find your local office

Select location
© 2025 Novo Nordisk A/S
Data Privacy
Cookie policy
Cookie settings

change